---
title: "UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics"
description: "Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260789673.md"
published_at: "2025-10-12T13:02:27.000Z"
---

# UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

> Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options

### Related Stocks

- [UNCY.US - Unicycive Therapeutics](https://longbridge.com/en/quote/UNCY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Unicycive is all-in on kidney care, focusing on underserved areas: CEO | Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a biotech firm focused on developing treatments for renal diseases, parti | [Link](https://longbridge.com/en/news/269443800.md) |
| Unicycive Therapeutics Showcases Pipeline Advancements in Kidney Disease Treatments | Unicycive Therapeutics Inc. has showcased its advancements in kidney disease treatments, particularly with oxylanthanum  | [Link](https://longbridge.com/en/news/274355130.md) |
| 10:23 ETINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics | Faruqi & Faruqi, LLP is investigating potential claims on behalf of investors in Aquestive Therapeutics, Inc. following  | [Link](https://longbridge.com/en/news/275920901.md) |
| 10:23 ETINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics | Faruqi & Faruqi, LLP is investigating potential claims on behalf of investors in Aquestive Therapeutics, Inc. after the  | [Link](https://longbridge.com/en/news/275206773.md) |
| Uncovering Potential: Karyopharm Therapeutics's Earnings Preview | Karyopharm Therapeutics (NASDAQ:KPTI) is set to release its quarterly earnings report on February 12, 2026, with analyst | [Link](https://longbridge.com/en/news/275648580.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.